Internal medicine

Virus

Immunotherapy

Lymphoma

Rituximab

Epstein–Barr virus

Hematopoietic cell

Biology

Adoptive cell transfer

Haematopoiesis

Refractory (planetary science)

Cytotoxic T cell

In vitro

Immunology

Hematopoietic stem cell transplantation

T cell

Stem cell

Transplantation

Adoptive immunotherapy

Cancer research

Genetics

Biochemistry

Medicine

Astrobiology

Immune system

Journal of Clinical Investigation

BACKGROUND. Adoptive transfer of donor-derived EBV-specific cytotoxic T-lymphocytes (EBV-CTLs) can eradicate EBV-associated lymphomas (EBV-PTLD) after transplantation of hematopoietic cell (HCT) or solid organ (SOT) but is unavailable for most patients.

Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation